Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 3.8% Higher
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 3.8% Higher
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating)'s share price traded up 3.8% during mid-day trading on Wednesday . The stock traded as high as $1.64 and last traded at $1.62. 801 shares were traded during mid-day trading, a decline of 95% from the average session volume of 16,446 shares. The stock had previously closed at $1.56.
Armata Pharmicals, Inc.(紐約證券交易所美國證券交易所代碼:ARMP — 獲取評級)的股價在週三午盤交易中上漲了3.8%。該股交易價格高達1.64美元,最後一次交易價格爲1.62美元。午盤交易中交易了801股,較平均交易量16,446股下降了95%。該股此前收於1.56美元。
Analysts Set New Price Targets
分析師設定了新的價格目標
Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Friday, March 17th.
另外,HC Wainwright在3月17日星期五的一份研究報告中重新發布了 “買入” 評級,並對Armata Pharmicals的股票發佈了7.00美元的目標價格。
Armata Pharmaceuticals Stock Up 3.8 %
Armata Pharmicals股票上漲3.8%
The company has a market cap of $58.53 million, a PE ratio of -1.49 and a beta of 1.18.
該公司的市值爲5853萬美元,市盈率爲-1.49,beta值爲1.18。
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating) last announced its earnings results on Thursday, March 16th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. Armata Pharmaceuticals had a negative return on equity of 75.16% and a negative net margin of 670.26%. On average, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.
Armata Pharmicals(NYSEAMERICAN: ARMP — 獲取評級)最後一次公佈財報是在3月16日星期四。該公司公佈了本季度每股收益(0.29美元),比分析師普遍預期的(0.25美元)低了(0.04美元)。該公司在本季度的收入爲105萬美元,而市場普遍預期爲134萬美元。Armata Pharmicals的負股本回報率爲75.16%,淨利潤率爲負670.26%。股票分析師平均預計,Armata Pharmicals, Inc.將在本財年公佈每股收益-1.31美元。
Institutional Trading of Armata Pharmaceuticals
阿瑪塔製藥的機構交易
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Armata Pharmaceuticals by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company's stock worth $1,335,000 after acquiring an additional 10,400 shares in the last quarter. Northern Trust Corp purchased a new position in Armata Pharmaceuticals during the first quarter worth approximately $95,000. Renaissance Technologies LLC increased its position in shares of Armata Pharmaceuticals by 5.6% in the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock worth $91,000 after acquiring an additional 3,900 shares in the last quarter. HRT Financial LP acquired a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $52,000. Finally, Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals during the 4th quarter valued at $25,000. Institutional investors and hedge funds own 3.76% of the company's stock.
一些對沖基金最近買入和賣出了該公司的股票。Vanguard Group Inc. 在第一季度將其在Armata Pharmicals的股份提高了4.0%。Vanguard Group Inc. 在上個季度又收購了10,400股股票後,現在擁有該公司273,150股股票,價值13.5萬美元。北方信託公司在第一季度收購了Armata Pharmicals的新職位,價值約9.5萬美元。Renaissance Technologies LLC在第四季度將其在Armata Pharmicals的股票頭寸增加了5.Renaissance Technologies LLC在上個季度又收購了3,900股股票後,現在擁有該公司73,696股股票,價值91,000美元。HRT Financial LP在第四季度收購了價值52,000美元的Armata Pharmicals股票的新股份。最後,Jane Street Group LLC在第四季度收購了Armata Pharmicals的新股份,價值25,000美元。機構投資者和對沖基金擁有該公司3.76%的股票。
Armata Pharmaceuticals Company Profile
阿瑪塔製藥公司簡介
(Get Rating)
(獲取評級)
Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Armata Pharmicals, Inc是一家臨床階段的生物技術公司,專注於開發用於治療耐藥細菌感染的噬菌體療法。該公司成立於2019年5月9日,總部位於加利福尼亞州洛杉磯。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
- 免費獲取 StockNews.com 關於 Armata Pharmicals(ARMP)的研究報告的副本
- ASML報告了大規模增長,管理層指出2023年表現疲軟
- 分析師 Boost 會讓洛克希德·馬丁公司的股價上漲、上漲和下跌嗎?
- Mullen Automotive:是玫瑰花的嗎?
- 多元化的雅培實驗室可能會逆轉並走高
- 催化劑接近時Okta的逆轉正在進行中
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收《阿瑪塔製藥日報》的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Armata Pharmicals及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。